Prominent front line critical care doctors have sued the federal government, including both the U.S. Department of Health and Human Services and the Food and Drug Administration (FDA), due to the latter’s effort to impede the use of ivermectin via a myriad of strategies and tactics from a sort of information warfare to threatening physicians livelihoods indirectly by communicating with licensing bodies that doctors should face reprimand, including the loss of license for engaging in any activity that includes the promulgation of misinformation. Filed in the U.S. Southern District of Texas in Galveston, plaintiffs include Dr. Mary Talley Bowden, Paul E. Marik, and Robert L. Apter.

As well-known proponents of early treatment and use of FDA-approved, off-label therapies to treat COVID-19, the plaintiffs argue that the FDA’s information warfare, including the use of social media to convey that ivermectin was a dangerous drug for human consumption, led to a purge of ivermectin-prescribing doctors as physician-licensing bodies started policing their members across many states.

The plaintiffs declare in the complaint that the FDA’s activity was outrageous, negligent, and outside of its mandated authority as federal bureaucrats. They claim the FDA illegally meddled with doctor and patient relationships to stop the use of ivermectin.

In a recent press conference, the Ear, Nose, and Throat specialist Dr. Bowden, who resides in Texas, declared that her early treatment intervention was responsible for keeping at least 3,900 COVID-19 patients out of the hospital thanks to the use of ivermectin and other complementary treatments.

TrialSite has reported some states such as Tennessee have recently passed laws allowing consumers to access ivermectin via a standing order at the pharmacy. But most states have shut down ivermectin access. Ivermectin subscriptions totaled about 3,000 per week before the pandemic and, according to one study, skyrocketed to nearly 90,000 per week during the height of the pandemic last year. A combination of FDA proactive pressure and disapproval of use by the leadership of academic medical centers, health systems, medical societies, and other stakeholders in organized medicine has led to a dramatic reduction in access to ivermectin as an off-label regiment for COVID-19.

Follow the link to read the lawsuit at the website of Boyden Gray & Associates.

https://www.trialsitenews.com/a/prominent-early-treatment-ivermectin-doctors-sue-fda-hhs-7162f7de